Clinic Roundup

• Asubio Pharmaceuticals Inc., of Paramus, N.J., started a Phase II trial of SUN13837, a therapy designed to improve neurological function in patients with newly diagnosed acute spinal cord injury. The company is working with 60 acute trauma centers throughout the U.S. and Canada to enroll 164 patients in the randomized, placebo-controlled trial.